Key market opportunities for Benlysta include strong growth momentum driven by sustained sales and strategic expansion into lupus nephritis. The shift to subcutaneous administration enhances patient ...

Cabaletta Bio (CABA) remains a Buy: rese-cel trial catalysts, autoimmune upside, scalable manufacturing, and key risks like ...

Quench Bio has emerged from stealth mode with $50 million of committed funding, bidding to be the first company to target Gasdermin D (GSDMD) in inflammatory disease indications poorly served by ...

GSK has posted a solid set of financial results in the first quarter of this year and said it is not too worried about the financial impact of potential pharma-specific US tariff rules. The ...

Despite expanding biologic use, nearly 60% of lupus patients report high disease activity, while rising costs and treatment ...

Note that some links may require registration or subscription. Ahead of a 2-day meeting of the Advisory Committee on Immunization Practices (ACIP) starting today, the CDC posted a report as part of ...

The FDA has approved AstraZeneca’s Saphnelo autoinjector for subcutaneous self-administration in adults with moderate to severe systemic lupus erythematosus (SLE) receiving standard therapy. The ...